Ralf J. Holzer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ralf J. Holzer has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Kimberlee Gauvreau
Boston Children’s Hospital, Boston, USA
5 shared publicationsLisa Bergersen
5 shared publicationsSara M. Trucco
UPMC Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, USA
5 shared publications- Sarosh Percy Batlivala
The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
4 shared publications - Susan Foerster
Division of Pediatric Cardiology, Children’s Wisconsin, Milwaukee (S.F.).
4 shared publications - Brian P. Quinn
Department of Cardiology Boston Children's Hospital Boston Massachusetts USA
3 shared publications
Latest Publications
- 17 October 2025
- Published by Springer Nature in Pediatric Cardiology
- Vol. 47 (7) , 1-9
Outcomes and Risk Factors of Transcatheter Interventions to Create or Enlarge an Atrial Communication
Despite interventions to enlarge/create an atrial communication having been performed for several decades, only a single larger multi-center study has reported procedural adverse events on at least 200 patients. Most studies have included associated interventions performed in the same setting and have not differentiated by procedural techniques, limiting the ability to derive conclusions from those reports. 432 cases from the C3PO-QI registry dataset from 01/2014 to 12/2017 who underwent interventions to enlarge/create an atrial communication were included (excluding patients with other interventions performed in the same setting). Patient- and procedure-specific data were analyzed, and risk factors for clinically meaningful adverse events (CMAE) were identified. 63% of interventions to enlarge/create an atrial communication were performed < = 30 days of age, 18% age 1–11 months, and 19% > = 1 year. 91% were non-elective procedures. For atrial access, 18% required needle or radiofrequency (RF) puncture. Balloon septostomy alone was performed in 73%, atrial septoplasty (± BAS) in 12%, and atrial stent or blade septostomy in 15%. CMAE occurred in 6.5% of cases (mortality 2%). By multivariable analysis, risk factors for CMAE were single ventricle and atrial needle or RF puncture. When analyzing neonates and patients one year of age or older separately, pre-procedural ECMO, single-ventricle physiology, atrial access via needle or RF puncture, and type of atrial intervention other than standard BAS, were all associated with an increased incidence of CMAE in neonates, but not in patients 1 year of age or older. Interventions to enlarge/create an atrial communication carry a risk of CMAE that varies by age group, with ECMO at the start, single-ventricle physiology, atrial access via needle or RF puncture, and type of atrial intervention anything other than standard BAS being significant risk factors for CMAE in neonates, but not in patients above 1 year of age.
- 17 October 2025
- Published by Springer Nature in Pediatric Cardiology
- Vol. 47 (7) , 1-9
Outcomes and Risk Factors of Transcatheter Interventions to Create or Enlarge an Atrial Communication
Despite interventions to enlarge/create an atrial communication having been performed for several decades, only a single larger multi-center study has reported procedural adverse events on at least 200 patients. Most studies have included associated interventions performed in the same setting and have not differentiated by procedural techniques, limiting the ability to derive conclusions from those reports. 432 cases from the C3PO-QI registry dataset from 01/2014 to 12/2017 who underwent interventions to enlarge/create an atrial communication were included (excluding patients with other interventions performed in the same setting). Patient- and procedure-specific data were analyzed, and risk factors for clinically meaningful adverse events (CMAE) were identified. 63% of interventions to enlarge/create an atrial communication were performed < = 30 days of age, 18% age 1–11 months, and 19% > = 1 year. 91% were non-elective procedures. For atrial access, 18% required needle or radiofrequency (RF) puncture. Balloon septostomy alone was performed in 73%, atrial septoplasty (± BAS) in 12%, and atrial stent or blade septostomy in 15%. CMAE occurred in 6.5% of cases (mortality 2%). By multivariable analysis, risk factors for CMAE were single ventricle and atrial needle or RF puncture. When analyzing neonates and patients one year of age or older separately, pre-procedural ECMO, single-ventricle physiology, atrial access via needle or RF puncture, and type of atrial intervention other than standard BAS, were all associated with an increased incidence of CMAE in neonates, but not in patients 1 year of age or older. Interventions to enlarge/create an atrial communication carry a risk of CMAE that varies by age group, with ECMO at the start, single-ventricle physiology, atrial access via needle or RF puncture, and type of atrial intervention anything other than standard BAS being significant risk factors for CMAE in neonates, but not in patients above 1 year of age.
- Open Access
- 21 January 2025
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 35 (1) , 162-169
Association between procedure duration and adverse events in congenital cardiac catheterization
Background: Procedure duration is an important predictor of patient outcomes in surgery. However, the relationship between procedure duration and adverse events in congenital cardiac catheterization is largely unexplored.Methods: All cases entered into the Congenital Cardiac Catheterization Project on Outcomes from 2014 to 2017 were included. Cases were ordered from shortest to longest case length, minus time spent managing adverse events, for each case type. The outcomes, Level 3bc/4/5 and 4/5 adverse event rates, were calculated for cases above and below the 75th percentile for case length. To identify an independent relationship between case length and outcomes, the case length percentile was added to the CHARM II risk model.Results: Among 14,704 catheterizations, longer cases (>75th percentile for case length) had Level 4/5 rates that were 2.2% and 2.7% compared to cases ≤75th percentile with adverse event rates of 0.9% and 1.4% for diagnostic and interventional cases, respectively. Level 3bc/4/5 rates were 5.0% and 8.4% in longer cases compared to 2.4% and 5.4% for diagnostic and interventional cases, respectively. After adding case length to the CHARM II risk model, case length 50th–75th percentile had an odds ratio (OR) of 1.4, 75th–90th percentile an OR of 1.56, and >90th percentile an OR of 2.24 as compared to cases with case length th percentile (p ≤ 0.001 for all).Conclusions: Longer case lengths are associated with clinically important and life-threatening adverse events in congenital cardiac catheterization, even after accounting for known risk factors. Case length may be an important target for future quality improvement work.
- 21 January 2025
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 35 (1) , 162-169
Open AccessAssociation between procedure duration and adverse events in congenital cardiac catheterization
Background: Procedure duration is an important predictor of patient outcomes in surgery. However, the relationship between procedure duration and adverse events in congenital cardiac catheterization is largely unexplored.Methods: All cases entered into the Congenital Cardiac Catheterization Project on Outcomes from 2014 to 2017 were included. Cases were ordered from shortest to longest case length, minus time spent managing adverse events, for each case type. The outcomes, Level 3bc/4/5 and 4/5 adverse event rates, were calculated for cases above and below the 75th percentile for case length. To identify an independent relationship between case length and outcomes, the case length percentile was added to the CHARM II risk model.Results: Among 14,704 catheterizations, longer cases (>75th percentile for case length) had Level 4/5 rates that were 2.2% and 2.7% compared to cases ≤75th percentile with adverse event rates of 0.9% and 1.4% for diagnostic and interventional cases, respectively. Level 3bc/4/5 rates were 5.0% and 8.4% in longer cases compared to 2.4% and 5.4% for diagnostic and interventional cases, respectively. After adding case length to the CHARM II risk model, case length 50th–75th percentile had an odds ratio (OR) of 1.4, 75th–90th percentile an OR of 1.56, and >90th percentile an OR of 2.24 as compared to cases with case length th percentile (p ≤ 0.001 for all).Conclusions: Longer case lengths are associated with clinically important and life-threatening adverse events in congenital cardiac catheterization, even after accounting for known risk factors. Case length may be an important target for future quality improvement work.
- Open Access
- 9 January 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 4 (2) , 102459
Evaluating Procedural Performance: A Composite Outcome for Atrial Septal Defect and Patent Ductus Arteriosus Closures
- 9 January 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 4 (2) , 102459
Open AccessEvaluating Procedural Performance: A Composite Outcome for Atrial Septal Defect and Patent Ductus Arteriosus Closures
- 13 September 2024
- Published by Taylor & Francis in Expert Review of Medical Devices
- Vol. 21 (10) , 903-913
Delivery systems for transcatheter therapies of congenital heart disease
IntroductionDelivery systems are crucially important for the implantation of medical devices in patients with congenital heart disease. However, very little data is available comparing the advantages and disadvantages of the various delivery systems.Areas coveredThis article describes the delivery systems and methods used for delivery of atrial septal occluder devices, ventricular septal occluder devices, devices to occlude patent arterial ducts, and transcatheter pulmonary valves. Delivery systems are compared relating to prepping and loading, positioning of the delivery sheath/catheter, deployment, ability to recapture and reposition, as well as device release.Expert opinionFor most ASD/VSD/PDA occluder devices, the basic delivery mechanism has changed very little over the preceding 20 years. Future modifications may focus on meaningful modifications to the cable systems that reduce stiffness and improve angulation at the connection to the device. Over the next 5-10 years, it is expected to see significant changes to delivery systems used for transcatheter pulmonary valve implantation, that result in improvements in the ability to recapture and reposition self-expandable transcatheter valves during the deployment process, combined with kink resistant sheaths that facilitate easy tracking across often complex right ventricular outflow tracts.
- 13 September 2024
- Published by Taylor & Francis in Expert Review of Medical Devices
- Vol. 21 (10) , 903-913
Delivery systems for transcatheter therapies of congenital heart disease
IntroductionDelivery systems are crucially important for the implantation of medical devices in patients with congenital heart disease. However, very little data is available comparing the advantages and disadvantages of the various delivery systems.Areas coveredThis article describes the delivery systems and methods used for delivery of atrial septal occluder devices, ventricular septal occluder devices, devices to occlude patent arterial ducts, and transcatheter pulmonary valves. Delivery systems are compared relating to prepping and loading, positioning of the delivery sheath/catheter, deployment, ability to recapture and reposition, as well as device release.Expert opinionFor most ASD/VSD/PDA occluder devices, the basic delivery mechanism has changed very little over the preceding 20 years. Future modifications may focus on meaningful modifications to the cable systems that reduce stiffness and improve angulation at the connection to the device. Over the next 5-10 years, it is expected to see significant changes to delivery systems used for transcatheter pulmonary valve implantation, that result in improvements in the ability to recapture and reposition self-expandable transcatheter valves during the deployment process, combined with kink resistant sheaths that facilitate easy tracking across often complex right ventricular outflow tracts.
- 6 June 2024
- Published by Springer Nature in Pediatric Cardiology
- Vol. 46 (3) , 736-739
PDA Stent Placement *6: High-Impact Limitations of Angiography to Delineate a Complex PDA
This is a case of an infant with duct-dependent pulmonary circulation, who required 6 stents delivered over three procedures to fully stent the arterial duct, which originated in a very unusual fashion. The attainable angiographic projections were unable to profile its origin, and only a CT scan was ultimately able to delineate the (stenotic) ductal origin from the aorta.
- 6 June 2024
- Published by Springer Nature in Pediatric Cardiology
- Vol. 46 (3) , 736-739
PDA Stent Placement *6: High-Impact Limitations of Angiography to Delineate a Complex PDA
This is a case of an infant with duct-dependent pulmonary circulation, who required 6 stents delivered over three procedures to fully stent the arterial duct, which originated in a very unusual fashion. The attainable angiographic projections were unable to profile its origin, and only a CT scan was ultimately able to delineate the (stenotic) ductal origin from the aorta.
- 1 March 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 17 (3) , e012834
Catheterization for Congenital Heart Disease Adjustment for Risk Method II
BACKGROUND: Current metrics used to adjust for case mix complexity in congenital cardiac catheterization are becoming outdated due to the introduction of novel procedures, innovative technologies, and expanding patient subgroups. This study aims to develop a risk adjustment methodology introducing a novel, clinically meaningful adverse event outcome and incorporating a modern understanding of risk. METHODS: Data from diagnostic only and interventional cases with defined case types were collected for patients ≤18 years of age and ≥2.5 kg at all Congenital Cardiac Catheterization Project on Outcomes participating centers. The derivation data set consisted of cases performed from 2014 to 2017, and the validation data set consisted of cases performed from 2019 to 2020. Severity level 3 adverse events were stratified into 3 tiers by clinical impact (3a/b/c); the study outcome was clinically meaningful adverse events, severity level ≥3b (3bc/4/5). RESULTS: The derivation data set contained 15 224 cases, and the validation data set included 9462 cases. Clinically meaningful adverse event rates were 4.5% and 4.2% in the derivation and validation cohorts, respectively. The final risk adjustment model included age P value, 0.83; Brier score, 0.042). CONCLUSIONS: CHARM II (Congenital Heart Disease Adjustment for Risk Method II) risk adjustment methodology allows for equitable comparison of clinically meaningful adverse events among institutions and operators with varying patient populations and case mix complexity performing pediatric cardiac catheterization.
- 1 March 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 17 (3) , e012834
Catheterization for Congenital Heart Disease Adjustment for Risk Method II
BACKGROUND: Current metrics used to adjust for case mix complexity in congenital cardiac catheterization are becoming outdated due to the introduction of novel procedures, innovative technologies, and expanding patient subgroups. This study aims to develop a risk adjustment methodology introducing a novel, clinically meaningful adverse event outcome and incorporating a modern understanding of risk. METHODS: Data from diagnostic only and interventional cases with defined case types were collected for patients ≤18 years of age and ≥2.5 kg at all Congenital Cardiac Catheterization Project on Outcomes participating centers. The derivation data set consisted of cases performed from 2014 to 2017, and the validation data set consisted of cases performed from 2019 to 2020. Severity level 3 adverse events were stratified into 3 tiers by clinical impact (3a/b/c); the study outcome was clinically meaningful adverse events, severity level ≥3b (3bc/4/5). RESULTS: The derivation data set contained 15 224 cases, and the validation data set included 9462 cases. Clinically meaningful adverse event rates were 4.5% and 4.2% in the derivation and validation cohorts, respectively. The final risk adjustment model included age P value, 0.83; Brier score, 0.042). CONCLUSIONS: CHARM II (Congenital Heart Disease Adjustment for Risk Method II) risk adjustment methodology allows for equitable comparison of clinically meaningful adverse events among institutions and operators with varying patient populations and case mix complexity performing pediatric cardiac catheterization.
- 20 February 2023
- Published by Springer Nature in Pediatric Cardiology
- Vol. 44 (4) , 795-805
The Need for Surgery After Vascular or Cardiac Trauma, or Technical Adverse Events in the Congenital Cardiac Catheterization Laboratory
Data on the frequency and outcome of surgical interventions as a result of adverse events (AE) encountered in the pediatric and congenital cardiac catheterization laboratory are limited. This study analyzes the outcomes of specific types of AE that are most likely to require immediate surgical intervention. Data from the C3PO registry were analyzed to identify specific types of significant vascular/cardiac trauma or technical adverse events (stent/device/coil embolization/migration). The relationship between these AE and an “adverse outcome” (defined as either surgery, ECMO, or death) were analyzed. Between 01/2014 and 12/2017, 25,731 cases were entered into the C3PO registry. Vascular or cardiac trauma were observed in 92 cases (0.36% cases in C3PO), and technical adverse events were observed in 176 cases (0.68% cases in C3PO). The two highest procedure type risk categories (PREDIC3T) accounted for 61% of the cases in the cardiac/vascular trauma cohort, and 34% in the technical AE cohort. For vascular/cardiac trauma, 24 (26%) had an adverse outcome, with ECMO in 8 (9%), surgery in 19 (20%), and death in 9 (10%). For technical AE 25 (14%) had an adverse outcome, with ECMO in 3 (2%), surgery in 23 (13%), and death in 3 (2%). Survival after cardiac surgery secondary to an AE was 68% for cardiac/vascular trauma, and 96% for technical adverse events. RF perforation of the pulmonary valve was the procedure most likely to result in cardiac/vascular trauma (10%), with 57% of those having an adverse outcome. Atrial septal interventions accounted for 29% of all adverse outcomes in the cardiac/vascular trauma cohort. Non-elective or emergent cases were associated with a significantly higher incidence of an adverse outcome for both, cardiac/vascular trauma (OR 7.1) and technical adverse events (OR 2.7). Surgery within the last 30 days was associated with a significantly higher incidence of an adverse outcome for cardiac/vascular trauma only (OR 4.2). Significant cardiac/vascular trauma or stent/device/coil embolization/migration are rare, but high consequence AE. With appropriate surgical and ECMO backup, a high survival can be achieved. The potential need for and impact of immediate surgical backup seems to be higher for cardiac/vascular trauma (in particular after specific case types), than for device/coil migration/embolization, and as such case specific backup arrangements are required.
- 20 February 2023
- Published by Springer Nature in Pediatric Cardiology
- Vol. 44 (4) , 795-805
The Need for Surgery After Vascular or Cardiac Trauma, or Technical Adverse Events in the Congenital Cardiac Catheterization Laboratory
Data on the frequency and outcome of surgical interventions as a result of adverse events (AE) encountered in the pediatric and congenital cardiac catheterization laboratory are limited. This study analyzes the outcomes of specific types of AE that are most likely to require immediate surgical intervention. Data from the C3PO registry were analyzed to identify specific types of significant vascular/cardiac trauma or technical adverse events (stent/device/coil embolization/migration). The relationship between these AE and an “adverse outcome” (defined as either surgery, ECMO, or death) were analyzed. Between 01/2014 and 12/2017, 25,731 cases were entered into the C3PO registry. Vascular or cardiac trauma were observed in 92 cases (0.36% cases in C3PO), and technical adverse events were observed in 176 cases (0.68% cases in C3PO). The two highest procedure type risk categories (PREDIC3T) accounted for 61% of the cases in the cardiac/vascular trauma cohort, and 34% in the technical AE cohort. For vascular/cardiac trauma, 24 (26%) had an adverse outcome, with ECMO in 8 (9%), surgery in 19 (20%), and death in 9 (10%). For technical AE 25 (14%) had an adverse outcome, with ECMO in 3 (2%), surgery in 23 (13%), and death in 3 (2%). Survival after cardiac surgery secondary to an AE was 68% for cardiac/vascular trauma, and 96% for technical adverse events. RF perforation of the pulmonary valve was the procedure most likely to result in cardiac/vascular trauma (10%), with 57% of those having an adverse outcome. Atrial septal interventions accounted for 29% of all adverse outcomes in the cardiac/vascular trauma cohort. Non-elective or emergent cases were associated with a significantly higher incidence of an adverse outcome for both, cardiac/vascular trauma (OR 7.1) and technical adverse events (OR 2.7). Surgery within the last 30 days was associated with a significantly higher incidence of an adverse outcome for cardiac/vascular trauma only (OR 4.2). Significant cardiac/vascular trauma or stent/device/coil embolization/migration are rare, but high consequence AE. With appropriate surgical and ECMO backup, a high survival can be achieved. The potential need for and impact of immediate surgical backup seems to be higher for cardiac/vascular trauma (in particular after specific case types), than for device/coil migration/embolization, and as such case specific backup arrangements are required.
- Open Access
- 1 July 2022
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 1 (5)
Procedural Characteristics and Outcomes of Transcatheter Interventions for Aortic Coarctation: A Report From the IMPACT Registry
- 1 July 2022
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 1 (5)
Open AccessProcedural Characteristics and Outcomes of Transcatheter Interventions for Aortic Coarctation: A Report From the IMPACT Registry
- 6 January 2022
- Published by Springer Nature in Pediatric Cardiology
- Vol. 43 (4) , 821-826
IMPACTing the Future: Are we on the Right Track?
More than ten years have passed since data collection was initiated in the IMPACT registry. Over the last decade, difficulties in data access and a lack of autonomy have led to a disengagement of the congenital community, with the usefulness of IMPACT to patients and providers being questioned. This article outlines some of problems identified using an online survey among interventional congenital cardiologists, and provides possible solutions for the future.
- 6 January 2022
- Published by Springer Nature in Pediatric Cardiology
- Vol. 43 (4) , 821-826
IMPACTing the Future: Are we on the Right Track?
More than ten years have passed since data collection was initiated in the IMPACT registry. Over the last decade, difficulties in data access and a lack of autonomy have led to a disengagement of the congenital community, with the usefulness of IMPACT to patients and providers being questioned. This article outlines some of problems identified using an online survey among interventional congenital cardiologists, and provides possible solutions for the future.